Humana (HUM) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Humana (NYSE: HUM):

• 4/22/2024 – Humana had its price target lowered by analysts at Jefferies Financial Group Inc. from $411.00 to $381.00. They now have a “buy” rating on the stock.
• 4/10/2024 – Humana had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $391.00 price target on the stock.
• 4/8/2024 – Humana had its price target lowered by analysts at Wells Fargo & Company from $413.00 to $350.00. They now have an “overweight” rating on the stock.
• 4/4/2024 – Humana had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $391.00 price target on the stock.
• 4/3/2024 – Humana had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $450.00 to $385.00. They now have a “buy” rating on the stock.
• 4/2/2024 – Humana had its “neutral” rating reaffirmed by analysts at Bank of America Co.. They now have a $342.00 price target on the stock, down previously from $470.00.
• 4/2/2024 – Humana had its price target lowered by analysts at Barclays PLC from $356.00 to $310.00. They now have an “equal weight” rating on the stock.
• 4/2/2024 – Humana had its price target lowered by analysts at TD Cowen from $427.00 to $396.00. They now have a “buy” rating on the stock.
• 3/22/2024 – Humana is now covered by analysts at Raymond James. They set a “market perform” rating on the stock.
• 3/13/2024 – Humana was downgraded by analysts at Argus from a “buy” rating to a “hold” rating.
• 3/6/2024 – Humana is now covered by analysts at Barclays PLC. They set an “equal weight” rating and a $356.00 price target on the stock.

Humana Price Performance

HUM stock traded down $11.94 on Wednesday, reaching $316.04. The company had a trading volume of 3,488,066 shares, compared to its average volume of 2,006,808. Humana Inc. has a 1 year low of $299.23 and a 1 year high of $541.21. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. The company’s fifty day moving average is $329.86 and its 200 day moving average is $398.38. The company has a market cap of $38.13 billion, a P/E ratio of 15.95, a PEG ratio of 1.91 and a beta of 0.45.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 19.44% and a net margin of 2.34%. The firm had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the prior year, the company earned $9.38 EPS. Humana’s revenue was up 10.7% on a year-over-year basis. On average, research analysts forecast that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 1.12%. Humana’s dividend payout ratio (DPR) is presently 17.86%.

Insider Buying and Selling at Humana

In other news, Director Jorge S. Mesquita acquired 545 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was acquired at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.29% of the stock is currently owned by insiders.

Institutional Trading of Humana

A number of institutional investors have recently added to or reduced their stakes in the business. Morgan Stanley boosted its position in Humana by 6.2% in the 3rd quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock valued at $992,938,000 after buying an additional 119,760 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Humana by 35.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after buying an additional 402,559 shares during the last quarter. Norges Bank purchased a new position in Humana in the 4th quarter valued at about $676,800,000. Northern Trust Corp boosted its position in Humana by 5.1% in the 3rd quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock valued at $645,850,000 after buying an additional 64,245 shares during the last quarter. Finally, Sanders Capital LLC purchased a new position in Humana in the 4th quarter valued at about $489,300,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.